Skip to main content
SpringerLink
Log in

Liver cancer

Sensitizing hepatocellular carcinoma to oncolytic virus therapy

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

Oncolytic viruses have made headlines owing to increasing numbers of reports of clinical success. Compelling data now indicate that small anticancer molecules can serve as potent sensitizers of tumour cells in hepatocellular carcinoma to enhance the oncolytic potential of systemically applied viruses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Valosin-containing protein inhibitors cooperate with M1 virus to trigger irresolvable endoplasmic reticulum stress and apoptosis in hepatocellular carcinoma cells.

References

  1. NCI-Staff. FDA approves talimogene laherparepvec to treat metastatic melanoma. National Cancer Institutehttps://www.cancer.gov/news-events/cancer-currents-blog/2015/t-vec-melanoma (2015).

  2. Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl Med. 9, eaam7996 (2017).

    Article  PubMed  Google Scholar 

  3. Lin, Y. et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl Acad. Sci. USA 111, E4504–E4512 (2014).

    Article  CAS  PubMed  Google Scholar 

  4. Li, K. et al. Activation of cyclic adenosine monophosphate pathway increases the sensitivity of cancer cells to the oncolytic virus M1. Mol. Ther. 24, 156–165 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Mahoney, D. J. et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20, 443–456 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Tardif, K. D. et al. Hepatitis C virus suppresses the IRE1–XBP1 pathway of the unfolded protein response. J. Biol. Chem. 279, 17158–17164 (2004).

    Article  CAS  PubMed  Google Scholar 

  7. Zhou, H. J. et al. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083). J. Med. Chem. 58, 9480–9497 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miest, T. S. & Cattaneo, R. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 12, 23–34 (2014).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar der TU München, Ismaningerstrasse 22, Munich, 81675, Germany

    Jennifer Altomonte

Authors
  1. Jennifer Altomonte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Altomonte.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altomonte, J. Sensitizing hepatocellular carcinoma to oncolytic virus therapy. Nat Rev Gastroenterol Hepatol 15, 8–10 (2018). https://doi.org/10.1038/nrgastro.2017.153

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.153

  • Springer Nature Limited

This article is cited by

Search

Navigation